Yuqi Kang

1.3k total citations · 2 hit papers
18 papers, 912 citations indexed

About

Yuqi Kang is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Yuqi Kang has authored 18 papers receiving a total of 912 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 6 papers in Oncology and 6 papers in Immunology. Recurrent topics in Yuqi Kang's work include RNA modifications and cancer (4 papers), Cancer-related gene regulation (4 papers) and Renal Diseases and Glomerulopathies (3 papers). Yuqi Kang is often cited by papers focused on RNA modifications and cancer (4 papers), Cancer-related gene regulation (4 papers) and Renal Diseases and Glomerulopathies (3 papers). Yuqi Kang collaborates with scholars based in United States, China and South Africa. Yuqi Kang's co-authors include Tariq M. Rana, Hui Hui, R. Tang, Na Li, Lingling Wang, Kriti Agrawal, Gwendolyn González, Yinsheng Wang, Sarah Huff and Sandip Pravin Patel and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and The EMBO Journal.

In The Last Decade

Yuqi Kang

16 papers receiving 904 citations

Hit Papers

ALKBH5 regulates anti–PD-1 therapy response by modulating... 2020 2026 2022 2024 2020 2020 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. ALKBH5 regulates anti–PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment
    2020 427 citations Na Li, Yuqi Kang et al. Proceedings of the National Academy of Sciences profile →
  2. m 6 A RNA methyltransferases METTL3/14 regulate immune responses to anti‐PD‐1 therapy
    2020 311 citations Lingling Wang, Hui Hui et al. The EMBO Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yuqi Kang United States 9 781 467 153 94 71 18 912
Liucun Gao China 14 473 0.6× 322 0.7× 167 1.1× 33 0.4× 24 0.3× 18 667
Ge Lou China 14 473 0.6× 225 0.5× 111 0.7× 66 0.7× 4 0.1× 27 595
Ilaria Fuso Nerini Italy 11 366 0.5× 237 0.5× 170 1.1× 33 0.4× 5 0.1× 14 607
Zhuonan Liu China 8 445 0.6× 159 0.3× 132 0.9× 53 0.6× 7 0.1× 12 529
Ingrid Babel Spain 8 301 0.4× 84 0.2× 137 0.9× 60 0.6× 16 0.2× 9 483
Muthana Al Abo United States 10 365 0.5× 71 0.2× 208 1.4× 42 0.4× 21 0.3× 15 439
Alessia Ricupito Italy 6 284 0.4× 231 0.5× 216 1.4× 300 3.2× 4 0.1× 7 599
Yanfang Yang China 8 413 0.5× 174 0.4× 99 0.6× 66 0.7× 4 0.1× 13 509

Countries citing papers authored by Yuqi Kang

Since Specialization
Citations

This map shows the geographic impact of Yuqi Kang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuqi Kang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuqi Kang more than expected).

Fields of papers citing papers by Yuqi Kang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuqi Kang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuqi Kang. The network helps show where Yuqi Kang may publish in the future.

Co-authorship network of co-authors of Yuqi Kang

This figure shows the co-authorship network connecting the top 25 collaborators of Yuqi Kang. A scholar is included among the top collaborators of Yuqi Kang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuqi Kang. Yuqi Kang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Nishida‐Aoki, Nao, Marina Chan, Yuqi Kang, et al.. (2025). Drug screening in 3D microtumors reveals DDR1/2-MAPK12-GLI1 as a vulnerability in cancer-associated fibroblasts. Cell Reports Medicine. 6(10). 102357–102357.
2.
Li, Xianzhi, Yuqi Kang, Xiaohan Yuan, et al.. (2025). Glomerular mesangial cells derived complement factor H regulates complement activation, influences cell proliferation, and maintains actin cytoskeleton. International Immunopharmacology. 154. 114544–114544. 1 indexed citations
3.
4.
Kang, Yuqi, Boyang Xu, Sufang Shi, et al.. (2023). Mesangial C3 Deposition, Complement-Associated Variant, and Disease Progression in IgA Nephropathy. Clinical Journal of the American Society of Nephrology. 18(12). 1583–1591. 10 indexed citations
5.
Li, Na, Yufei Deng, R. Tang, et al.. (2023). KIAA1429 / VIRMA promotes breast cancer progression by m 6 A ‐dependent cytosolic HAS2 stabilization. EMBO Reports. 24(10). e55506–e55506. 14 indexed citations
6.
O’Brien, Valerie P., Yuqi Kang, Meera K. Shenoy, et al.. (2023). Single-cell Profiling Uncovers a Muc4 -Expressing Metaplastic Gastric Cell Type Sustained by Helicobacter pylori -driven Inflammation. Cancer Research Communications. 3(9). 1756–1769. 3 indexed citations
7.
Kang, Yuqi, Li Zhu, Mengyuan Yuan, et al.. (2023). Longitudinal correlates of bullying victimization among Chinese early adolescents: A cross-lagged panel network analysis. Journal of Affective Disorders. 339. 203–210. 7 indexed citations
8.
9.
Kang, Yuqi, et al.. (2023). Polypharmacology-based kinome screen identifies new regulators of KSHV reactivation. PLoS Pathogens. 19(9). e1011169–e1011169. 4 indexed citations
10.
Robesti, Daniele, Eva Corey, Mark Titus, et al.. (2022). Subtype and Site Specific–Induced Metabolic Vulnerabilities in Prostate Cancer. Molecular Cancer Research. 21(1). 51–61. 7 indexed citations
11.
Kang, Yuqi, et al.. (2022). Deep neural network modeling identifies biomarkers of response to immune-checkpoint therapy. iScience. 25(5). 104228–104228. 14 indexed citations
12.
Xu, Boyang, Yuqi Kang, Yujing Du, et al.. (2022). Atypical Hemolytic Uremic Syndrome-Associated FHR1 Isoform FHR1*B Enhances Complement Activation and Inflammation. Frontiers in Immunology. 13. 2 indexed citations
13.
Zhang, Qiong, Yuqi Kang, Shaobo Wang, et al.. (2021). HIV reprograms host m6Am RNA methylome by viral Vpr protein-mediated degradation of PCIF1. Nature Communications. 12(1). 5543–5543. 40 indexed citations
14.
Wang, Lingling, Hui Hui, Kriti Agrawal, et al.. (2020). m 6 A RNA methyltransferases METTL3/14 regulate immune responses to anti‐PD‐1 therapy. The EMBO Journal. 39(20). e104514–e104514. 311 indexed citations breakdown →
15.
Li, Na, Yuqi Kang, Lingling Wang, et al.. (2020). ALKBH5 regulates anti–PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment. Proceedings of the National Academy of Sciences. 117(33). 20159–20170. 427 indexed citations breakdown →
16.
Zhang, Bing, et al.. (2020). Astragaloside IV alleviates puromycin aminonucleoside-induced podocyte cytoskeleton injury through the Wnt/PCP pathway.. PubMed. 12(7). 3512–3521. 9 indexed citations
17.
18.
Wang, Rui, et al.. (2018). Hydrogen Sulfide Demonstrates Promising Antitumor Efficacy in Gastric Carcinoma by Targeting MGAT5. Translational Oncology. 11(4). 900–910. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Liucun Gao Breakdown of academic impact, for papers by Ge Lou Breakdown of academic impact, for papers by Ilaria Fuso Nerini Breakdown of academic impact, for papers by Zhuonan Liu Breakdown of academic impact, for papers by Ingrid Babel Breakdown of academic impact, for papers by Muthana Al Abo Breakdown of academic impact, for papers by Alessia Ricupito Breakdown of academic impact, for papers by Yanfang Yang
Rankless by CCL
2026